Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Postel

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2017
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout SurveyS Banerjee, R Califano, J Corral, et al.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewJ M Michot, C Bigenwald, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancersM M Gounder, P Martin-Romano, A Italiano, et al.
The Annals of Occupational Hygiene|December 24, 2010
Workplace bullying and psychotropic drug use: the mediating role of physical and mental health statusIsabelle Niedhammer, Simone David, Stéphanie Degioanni, et al.
Sleep|September 16, 2009
Workplace bullying and sleep disturbances: findings from a large scale cross-sectional survey in the French working populationIsabelle Niedhammer, Simone David, Stephanie Degioanni, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2017
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout SurveyS Banerjee, R Califano, J Corral, et al.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewJ M Michot, C Bigenwald, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancersM M Gounder, P Martin-Romano, A Italiano, et al.
The Annals of Occupational Hygiene|December 24, 2010
Workplace bullying and psychotropic drug use: the mediating role of physical and mental health statusIsabelle Niedhammer, Simone David, Stéphanie Degioanni, et al.
Sleep|September 16, 2009
Workplace bullying and sleep disturbances: findings from a large scale cross-sectional survey in the French working populationIsabelle Niedhammer, Simone David, Stephanie Degioanni, et al.
Pageof 4